Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
NEW YORK, April 18, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Platform Specialty Products Corporation (“Platform”) (NYSE:PAH) between February 17, 2015 and March 14, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of Florida. If you purchased or otherwise acquired Platform securities between February 17, 2015 and March 14, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/platform-specialty-products-corporation.
On February 17, 2015, Platform completed its acquisition of Arysta LifeScience Limited. The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Arysta made improper third-party payments in West Africa; (2) such payments were unlawful under the U.S. Foreign Corrupt Practices Act; and (3) as a result, Platforms’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Platform you have until June 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/platform-specialty-products-corporation.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
